Literature DB >> 25027758

Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status.

Lene Rask1, Eva Balslev, Rolf Søkilde, Estrid Høgdall, Henrik Flyger, Jens Eriksen, Thomas Litman.   

Abstract

PURPOSE: Therapeutic decisions in breast cancer are increasingly guided by prognostic and predictive biomarkers. Non-protein-coding microRNAs (miRNAs) have recently been found to be deregulated in breast cancers and, in addition, to be correlated with several clinico-pathological features. One of the most consistently up-regulated miRNAs is miR-21. Here, we specifically searched for differentially expressed miRNAs in high-risk breast cancer patients as compared to low-risk breast cancer patients. In the same patients, we also compared miR-21 expression with the expression of its presumed target PTEN.
METHODS: Both microarray and RT-qPCR techniques were used to assess miRNA expression levels in lymph node-positive and -negative human invasive ductal carcinoma tissues. Simultaneously, PTEN protein expression levels were assessed using immunohistochemistry.
RESULTS: miR-486-5p and miR-139-5p were found to be down-regulated in patients with lymph node metastases, whereas miR-21 was found to be up-regulated in patients with a positive lymph node status. miR-21 expression levels were found to significantly correlate with tumour size (r = 0.403, p = 0.009; Spearman's rank), whereas no relation was found between miR-21 and PTEN expression levels (Kruskal-Wallis test).
CONCLUSION: Down-regulation of miR-486-5p and miR-139-5p, in conjunction with up-regulation of miR-21, may represent a useful signature for the identification of high-risk breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25027758     DOI: 10.1007/s13402-014-0176-6

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  60 in total

1.  Agilent microRNA microarray profiling system.

Authors:  Petula N D'Andrade; Stephanie Fulmer-Smentek
Journal:  Methods Mol Biol       Date:  2012

Review 2.  The widespread regulation of microRNA biogenesis, function and decay.

Authors:  Jacek Krol; Inga Loedige; Witold Filipowicz
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

3.  miR-31 in cancer: location matters.

Authors:  Christina H Stuelten; David S Salomon
Journal:  Cell Cycle       Date:  2010-12-01       Impact factor: 4.534

4.  Robust global microRNA expression profiling using next-generation sequencing technologies.

Authors:  Shirley Tam; Richard de Borja; Ming-Sound Tsao; John D McPherson
Journal:  Lab Invest       Date:  2014-01-20       Impact factor: 5.662

Review 5.  MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs.

Authors:  Achim Aigner
Journal:  J Mol Med (Berl)       Date:  2011-01-14       Impact factor: 4.599

Review 6.  Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms.

Authors:  Suzanne Eccles; Lenaic Paon; Jonathan Sleeman
Journal:  Clin Exp Metastasis       Date:  2007-11-06       Impact factor: 5.150

7.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.

Authors:  Shuomin Zhu; Hailong Wu; Fangting Wu; Daotai Nie; Shijie Sheng; Yin-Yuan Mo
Journal:  Cell Res       Date:  2008-03       Impact factor: 25.617

8.  MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1).

Authors:  Shuomin Zhu; Min-Liang Si; Hailong Wu; Yin-Yuan Mo
Journal:  J Biol Chem       Date:  2007-03-15       Impact factor: 5.157

9.  Real-time quantification of microRNAs by stem-loop RT-PCR.

Authors:  Caifu Chen; Dana A Ridzon; Adam J Broomer; Zhaohui Zhou; Danny H Lee; Julie T Nguyen; Maura Barbisin; Nan Lan Xu; Vikram R Mahuvakar; Mark R Andersen; Kai Qin Lao; Kenneth J Livak; Karl J Guegler
Journal:  Nucleic Acids Res       Date:  2005-11-27       Impact factor: 16.971

10.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies.

Authors:  Michael D Mattie; Christopher C Benz; Jessica Bowers; Kelly Sensinger; Linda Wong; Gary K Scott; Vita Fedele; David Ginzinger; Robert Getts; Chris Haqq
Journal:  Mol Cancer       Date:  2006-06-19       Impact factor: 27.401

View more
  32 in total

1.  Inhibition of miR-21 rescues liver regeneration after partial hepatectomy in ethanol-fed rats.

Authors:  Egle Juskeviciute; Rachael P Dippold; Anil N Antony; Aditi Swarup; Rajanikanth Vadigepalli; Jan B Hoek
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-15       Impact factor: 4.052

2.  Myoepithelial and luminal breast cancer cells exhibit different responses to all-trans retinoic acid.

Authors:  Damián E Berardi; Carolina Flumian; Paola B Campodónico; Alejandro J Urtreger; María I Diaz Bessone; Andrea N Motter; Elisa D Bal de Kier Joffé; Eduardo F Farias; Laura B Todaro
Journal:  Cell Oncol (Dordr)       Date:  2015-06-05       Impact factor: 6.730

Review 3.  Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.

Authors:  Mohammad Shahjahani; Javad Mohammadiasl; Fatemeh Noroozi; Mohammad Seghatoleslami; Saeid Shahrabi; Fakhredin Saba; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-01-07       Impact factor: 6.730

4.  MicroRNAs hsa-miR-495-3p and hsa-miR-486-5p suppress basal and rifampicin-induced expression of human sulfotransferase 2A1 (SULT2A1) by facilitating mRNA degradation.

Authors:  Dongying Li; Bridgett Knox; Si Chen; Leihong Wu; William H Tolleson; Zhichao Liu; Dianke Yu; Lei Guo; Weida Tong; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2019-08-22       Impact factor: 5.858

5.  miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.

Authors:  Insaf Fkih M'hamed; Maud Privat; Mounir Trimeche; Frédérique Penault-Llorca; Yves-Jean Bignon; Abderraouf Kenani
Journal:  Pathol Oncol Res       Date:  2017-01-18       Impact factor: 3.201

6.  KLF15 in breast cancer: a novel tumor suppressor?

Authors:  Tomomi Yoda; Keely May McNamara; Yasuhiro Miki; Yoshiaki Onodera; Kiyoshi Takagi; Yasuhiro Nakamura; Takanori Ishida; Takashi Suzuki; Noriaki Ohuchi; Hironobu Sasano
Journal:  Cell Oncol (Dordr)       Date:  2015-04-14       Impact factor: 6.730

7.  MicroRNA-139-3p indicates a poor prognosis of colon cancer.

Authors:  Xiaojing Liu; Bensong Duan; Yuanyuan Dong; Chengzhi He; Hongmei Zhou; Haihui Sheng; Hengjun Gao; Xizhi Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 8.  MiR-139-5p: promising biomarker for cancer.

Authors:  He-da Zhang; Lin-hong Jiang; Da-wei Sun; Jian Li; Jin-hai Tang
Journal:  Tumour Biol       Date:  2015-02-19

9.  Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas.

Authors:  E Prodromaki; A Korpetinou; E Giannopoulou; E Vlotinou; Μ Chatziathanasiadou; N I Papachristou; C D Scopa; H Papadaki; H P Kalofonos; D J Papachristou
Journal:  Cell Oncol (Dordr)       Date:  2015-07-31       Impact factor: 6.730

10.  The carboxy-terminal domain of connexin 43 (CT-Cx43) modulates the expression of p53 by altering miR-125b expression in low-grade human breast cancers.

Authors:  Raihana Maqbool; Rabiya Rashid; Rehana Ismail; Saif Niaz; Nisar Ahmad Chowdri; Mahboob Ul Hussain
Journal:  Cell Oncol (Dordr)       Date:  2015-09-03       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.